Our Company was founded in 1998 on the belief that autologous point-of-care therapies are the preferred standard of care for both patient and physician. With this experience and an understanding of how the body heals itself, in 2000 SafeBlood Technologies redirected our focus exclusively to non-healing chronic wounds.

SafeBlood® Technologies dedication to results-based medicine and cost containment has lead to the development of a unique program that features a multi-disciplined approach for the treatment of both acute and chronic non-healing wounds. Our protocols begin with inclusion criteria and eligibility documentation followed by instruction on application of PlasmaDerm WD™, featuring the SafeBlood Graft,™ or our version of PRP. Standardized operating procedures can be developed based on facility specific formularies for care/treatment cycles that include appropriate dressings based on wound etiology. Documentation templates are available to track and automatically chart a wound's progress. Physician consultants are available to discuss and instruct in proper grafting technique.

SafeBlood® Technologies has offered training and support of autologous (from one’s self) cellular rich biologics for over ten years. We work as a facilitator for the successful implementation of this therapy. Publications by various facilities about their implementation of this therapy and successful outcomes in outpatient wound care clinics, ambulatory surgery centers and, for the last six years, in long term acute hospitals can be found on this site.

We hope the following information will be of benefit to medical professionals and patients alike. Thank you again for your time and interest. For additional clinical or regulatory information, please feel free to register for access to our information library.

Sincerely, Jim Limbird, President SafeBlood® Technologies Inc.